

RECEIVED  
CENTRAL FAX CENTER

04:08:35 p.m.

09-05-2006

3/18

SEP 05 2006

PTO/SB/08a (07-05)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/576,142		
		Filing Date	4/18/2006		
		First Named Inventor	Arendt, et al.		
		Art Unit	Not yet assigned		
		Examiner Name	Not yet assigned		
Sheet	1	of	1	Attorney Docket Number	4121-180

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup>	Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	AA	DE	- 199 38 035- A1 (Abstract)	02-08-2001	Arendt, Thomas		

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AB	ANDROSOVA, L.V., ET AL., [Correlation between functional activity of lymphocytes in patients with Alzheimer's dementia and their response to...], Zh Nevrol Psikhiatr Im S S Korsakova (Article in Russian-English abstract available on Medline), 1998, Page(s) 43-46, Volume 98, Number 5	
	AC	LOMBARDI, V.R.M., ET AL., Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy..., J. Neuroimmunol., June 1, 1999, Page(s) 163-171, Volume 97, Number 1-2	
	AD	PONOMOREVA, N.V., ET AL., [Neuroimmune interactions in normal aging and in Alzheimer disease], Vestn Ross Akad Med Nauk (Article in Russian-English abstract available on Medline), 1995, Page(s) 27-32, Number 12	
	AE	SHALIT, F., ET AL., T Lymphocyte Subpopulations and Activation Markers Correlate with Severity of Alzheimer's Disease, Clinical Immunol. Immunopathol., June 1995, Page(s) 246-250, Volume 75, Number 3	
	AF	STIELER, JENS T., ET AL., Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer's disease, Neuroreport, December 21, 2001, Page(s) 3969-3972, Volume 12, Number 18	

Examiner Signature	/Stacey Macfarlane/	Date Considered	07/24/2008
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.M./